Post A Reply
my profile
login
|
register
|
search
|
faq
|
forum home
»
Allstocks.com's Bulletin Board
»
.11 and Up!
»
NRGX Gene therapy
» Post A Reply
Post A Reply
Login Name:
Password:
Message Icon:
Message:
HTML is enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by BooDog: [QB] 24-Jan-2008 Other Events Item 8.01. Other Events. Plan of Operation- - Epilepsy As a result of recent comments from, and discussions with, the Food and Drug Administration ("FDA") with respect to the Investigational New Drug ("IND") application filed by Neurologix, Inc. (the "Company") for a Phase I clinical trial in temporal lobe epilepsy, the Company has decided to conduct an additional preclinical study in non-human primates. Such study will be designed to confirm the safety of the administration and use of the adeno-associated virus expressing Neuropeptide Y (rAAV1-NPY). The Company plans to work closely with the FDA to design a protocol with respect to this additional preclinical study, and until such protocol is agreed upon, the Company is unable to estimate the total time or costs involved in conducting such trial. In this regard, the commencement of its Phase I clinical trial will depend on the successful completion of this additional preclinical study. At the present time, the Company does not, however, expect that the study will result in significant changes to the protocol submitted by it to the FDA for the Phase I clinical trial. (See "Risk Factors - The Company Cannot Ensure that it Can Pursue Subsequent Trials for its Product Candidates or the Timing of any such Trials"; "Risk Factors - The Company is Subject to Stringent Regulation; FDA Approvals"; and "Risk Factors - The Company Will Need to Conduct Significant Additional Research and Testing Before Conducting Clinical Trials Involving Future Product Candidates" in the Company's 2006 Form 10-KSB). NEUROLOGIX INC (OTC BB:NRGX.OB) Last Trade: 1.10 Trade Time: Jan 23 Change: 0.00 (0.00%) Prev Close: 1.10 Open: N/A Bid: N/A Ask: N/A 1y Target Est: N/A Day's Range: N/A - N/A 52wk Range: 0.60 - 4.50 Volume: 0 Avg Vol (3m): 16,381 Market Cap: 29.58M P/E (ttm): N/A EPS (ttm): -0.28 Div & Yield: N/A (N/A) [/QB][/QUOTE]
Instant Graemlins
Instant UBB Code™
What is UBB Code™?
Options
Disable Graemlins in this post.
*** Click here to review this topic. ***
Contact Us
|
Allstocks.com Message Board Home
© 1997 - 2021 Allstocks.com. All rights reserved.
Powered by
Infopop Corporation
UBB.classic™ 6.7.2